Eli Lilly and Company
- Homepage: http://www.lilly.com/
May 2002: "Lilly is a leader in the pharmaceutical industry. The company employs more than 41,000 people worldwide and markets its medicines in 158 countries. Obtain facts and information here that describe our company and its operations." http://www.lilly.com/about/index.html
March 2010: "In January 2009, Indianapolis-based Lilly, the largest U.S. psychiatric drugmaker, pleaded guilty and paid $1.42 billion in fines and penalties to settle charges that it had for at least four years illegally marketed Zyprexa, a drug approved for the treatment of schizophrenia, as a remedy for dementia in elderly patients."http://www.washingtonpost.com/wp-dyn/content/article/2010/03/19/AR2010031905578.html
October 2008: "In the case of GH, sales between 2002 and 2006 by one of GH’s makers, Eli Lilly, jumped 40 percent, to $460 million. In some cases, drug companies have crossed the line. In 1999, another GH maker, Genentech, pleaded guilty to federal criminal charges that it had improperly promoted GH, and ended up paying a $50 million fine. Nevertheless, many other lifestyle drugs continue to grow in sales at double-digit rates."http://www.salon.com/env/vital_signs/2008/10/31/growth_hormones_kids/index.html
April 2008: 'Speakers’ bureaus and drug samples are central pillars of the industry’s marketing operations, and many medical school professors have resisted efforts to restrict them....“We continue to believe that these types of programs, which are subject to clear regulations regarding their content, can be worthwhile educational activities,” wrote Jeffrey B. Kindler of Pfizer and Sidney Taurel of Lilly.'http://www.nytimes.com/2008/04/28/health/27cnd-doctors.html
March 2008: "But Lilly has faced mounting legal problems over Zyprexa as evidence of the drug’s tendency to cause weight gain and diabetes has emerged. Lilly has already spent about $1.2 billion to settle about 30,000 claims from people who say that Zyprexa caused them to develop diabetes or other diseases."http://www.nytimes.com/2008/03/06/business/06drug.html
April 2007: The discrepancy between Lilly’s initial data and what it later submitted came at a time when Zyprexa’s sales were soaring, even as some doctors and foreign regulatory agencies were questioning the drug’s safety.http://www.nytimes.com/2007/04/25/business/25zyprexa.html
March 2007: Lilly says it does not generally require a state to allow unfettered access to Zyprexa before offering the programs. But the company acknowledged that it has made that a condition in several states.http://www.nytimes.com/2007/03/23/business/23lilly.html
November 2006: Lilly, the sixth-largest American drug maker, reported two weeks ago that its third-quarter sales had risen 7 percent, to $3.9 billion, and its profits were up 10 percent, to $874 million, compared with 2005. According to Lilly’s published review of the quarter, the sales gains resulted almost entirely from Lilly’s prices rising 11 percent in the United States, while actually falling in Europe and Japan.http://www.nytimes.com/2006/11/06/business/06drug.html
November 2005: As part of a House budget bill that reduces spending on Medicaid prescription drugs, pharmaceutical giant Eli Lilly and Co. and other businesses secured a provision ensuring that their mental health drugs continue to fetch top price at a cost of hundreds of millions of dollars to the states.http://www.washingtonpost.com/wp-dyn/content/article/2005/11/29/AR2005112901650.html
Role Name Type Last Updated Organization Executive (past or present) Gov. Mitchell E. Daniels Jr., Esq. Person Jun 15, 2006 Organization Head/Leader (past or present) Ambassador Randall Tobias Person Apr 29, 2004
Articles and Resources
29 Articles and Resources. Go to: [Next 9]
Date Fairness.com Resource Read it at: Mar 21, 2010 When drug makers' profits outweigh penalties
QUOTE: As large as the penalties are for drug companies caught breaking the off-label law, the fines are tiny compared with the firms' annual revenue. The $2.3 billion in fines and penalties Pfizer paid for marketing Bextra and three other drugs cited in the Sept. 2 plea agreement for off-label uses amount to just 14 percent of its $16.8 billion in revenue from selling those medicines from 2001 to 2008.
Bloomberg News Aug 01, 2009 Adaptive Evolution: A once-rare type of clinical trial that violates one of the sacred tenets of trial design is taking off, but is it worth the risk?
QUOTE: in an increasingly common approach, a trial can be altered in various ways while it’s still in progress... Such modifications are based on a peek at interim data—which of necessity means unblinding the data before the trial’s completion.
Scientist, The (TS) Jul 06, 2009 Familiar Players in Health Bill Lobbying: Firms Are Enlisting Ex-Lawmakers, Aides
QUOTE: The nation's largest insurers, hospitals and medical groups have hired more than 350 former government staff members and retired members of Congress in hopes of influencing their old bosses and colleagues.... public interest groups and reform advocates complain that the concentration of former government aides on K Street has distorted the health-care debate,
Washington Post Jun 12, 2009 Lilly Sold Drug for Dementia Knowing It Didn’t Help, Files Show
QUOTE: Eli Lilly & Co. urged doctors to prescribe Zyprexa for elderly patients with dementia... even though the drugmaker had evidence the medicine didn’t work for such patients...
Oct 31, 2008 Growth hormones for kids: Normal boys and girls are taking growth hormones for being short. That’s a bad prescription.
QUOTE: There is an ethical dilemma to consider about GH and the entire lifestyle drug market. Once a lifestyle drug is readily available and widely consumed, it can lead to a shift in what society considers normal. If height can be enhanced by "plastic endocrinologists" for the right price, we're redefining normal, and leaving those who can't afford these services behind.
Salon Apr 27, 2008 Group Urges Ban on Industry Gifts at Medical Schools
QUOTE: Drug and medical device companies should be banned from offering free food, gifts, travel and ghost-writing services to doctors, staff and students in all 129 of the nation’s medical colleges...The proposed ban is the result of a two-year effort by the Association of American Medical Colleges to create a model policy governing interactions between the schools and industry.
New York Times Mar 06, 2008 In Trial, Alaska Says Lilly Concealed Risks of a Schizophrenia Drug
QUOTE: ...memorandums from Lilly executives showed that the company knew of Zyprexa’s dangers soon after the drug was introduced in 1996. But Lilly deliberately played down the side effects, [the plantiff's lawyer] said, so that sales of Zyprexa would not be hurt.
New York Times Jan 17, 2008 Antidepressant Studies Unpublished
QUOTE: The makers of antidepressants like Prozac and Paxil never published the results of about a third of the drug trials that they conducted to win government approval, misleading doctors and consumers about the drugs’ true effectiveness, a new analysis has found.
New York Times Jan 14, 2008 Drug Approved. Is Disease Real?
QUOTE: For patient advocacy groups and doctors who specialize in fibromyalgia, the Lyrica approval is a milestone. They say they hope Lyrica...will legitimize fibromyalgia, just as Prozac brought depression into the mainstream. But other doctors...say that the disease does not exist and that Lyrica and the other drugs will be taken by millions of people who do not need them.
New York Times Jun 15, 2007 Are Pharmas Addicted to Lifestyle Drugs?: Drugmakers are eager to spiff up your sex life and hairline, even as their lucrative products face mounting safety questions
QUOTE: Try as they might to distance themselves from the lifestyle drug sector, pharmaceutical companies can't seem to kick their addiction to these lucrative products. Even as consumers and government regulators grow more alarmed over drug safety, an examination of four popular lifestyle categories—weight loss, hair loss, sleep, and sexual dysfunction—shows that the pharmaceutical industry is by no means shying away from this controversial territory.
BusinessWeek Apr 25, 2007 U.S. Wonders if Drug Data Was Accurate
QUOTE: The F.D.A. has questions about a Lilly document from February 2000 in which the company found that patients taking Zyprexa in clinical trials were three and a half times as likely to develop high blood sugar as those who did not take the drug. That document was not submitted to the agency. But a few months later, Lilly provided data to the F.D.A. that showed almost no difference in blood sugar between patients who took Zyprexa and those who did not.
New York Times Mar 23, 2007 In Some States, Maker Oversees Use of Its Drug
QUOTE: Medicaid administrators in some states say that Lilly has saved them money through the program, which it pays a consulting company to run. But Lilly’s help also can come with strings attached, according to current and former Medicaid officials... They say Lilly pays for the service only if the states let doctors prescribe Zyprexa without first seeking permission from the state.
New York Times Nov 06, 2006 As Drug Prices Climb, Democrats Find Fault With Medicare Plan
QUOTE: "Democrats, who have long charged that the drug industry is profiteering at taxpayers’ expense, say they want to introduce legislation to revoke the law that bars Medicare from negotiating prices directly with drug makers like Pfizer for the medicines it buys."
New York Times Jul 13, 2006 Mass-Tort Designation Sought for Anti-Psychotic Drug Suits
QUOTE: Facing a caseload of 235 claims against anti-psychotic drugs Risperdal, Seroquel and Zyprexa that could run into millions of dollars, Superior Court Judge Bryan Garruto has asked the state Supreme Court to roll up the litigation into a single mass tort...Russell Rein, whose Pensacola, Fla.-based firm Aylstock, Witkin & Sasser is representing three plaintiffs in the state litigation, says mass tort classification may benefit the defendant drug companies, since each of their witnesses could make a single deposition, instead of giving separate testimony in each case.
Law.com Jun 21, 2006 Firms Seek Federal Privacy Rules: 12 Big Businesses Say 'Patchwork' of State Laws Is Confusing
QUOTE: Several large technology companies, including Google Inc. and eBay Inc., announced support yesterday for stronger federal regulations to protect consumer privacy on the Internet.
Washington Post May 08, 2006 Chemist's New Product Contains Hidden Substance
QUOTE: Patrick Arnold...runs a company that has been selling the amphetamine-like compound over the Internet in a dietary supplement that describes the substance with the invented trademark name Geranamine...It is illegal to sell dietary supplements without listing the ingredients by their common or usual names...
Washington Post Apr 12, 2006 Comparison of Schizophrenia Drugs Often Favors Firm Funding Study
QUOTE: Pharmaceutical giant Eli Lilly and Co. recently funded five studies that compared its antipsychotic drug Zyprexa with ... a competing drug ... All five showed Zyprexa was superior in treating schizophrenia...when psychiatrist John Davis analyzed every publicly available trial funded by the pharmaceutical industry pitting five new antipsychotic drugs against one another, nine in 10 showed that the best drug was the one made by the company funding the study.
Washington Post Nov 30, 2005 Drugmakers Win Exemption in House Budget-Cutting Bill
QUOTE: The provision -- inserted by Rep. Steve Buyer (R-Ind.), whose district flanks Lilly's Indianapolis headquarters -- would largely exempt antipsychotic and antidepressant medications from a larger measure designed to steer Medicaid patients to the least expensive treatment options.
Washington Post Nov 15, 2005 A Self-Effacing Scholar Is Psychiatry's Gadfly
QUOTE: Dr. David Healy, a psychiatrist at the University of Cardiff and a vocal critic of his profession's overselling of psychiatric drugs, has achieved a rare kind of scientific celebrity: he is internationally known as both a scholar and a pariah.
New York Times Oct 08, 2005 Psychiatric Drugs' Use Drops for Children: Suicide Warnings Raise Bigger Fears On Testing Process
QUOTE: The fundamental problem, many experts said, is that there are not enough systematic long-term studies about psychiatric drugs.
29 Articles and Resources. Go to: [Next 9]
- Arts & Humanities
- Businesses & Organizations
- Computers & Information Technology
- Family & Friends & Interpersonal
- Government & Politics / History
- Health & Medicine
- Law & Justice
- Media & Journalism
- Personal Finance & Career
- Philosophy & Religion
- Recreation & Entertainment
- Science & Technology
- Social Sciences & Groups
- Arctic / Antarctic / Greenland
- Central America / Caribbean
- Eurasia / Central Asia
- Middle East
- North America
- Oceania / AustralAsia
- South America
- About Fairness.com
- Contact Us
- Conditions of Service
- Fair Use Notice
- Advisory Board
Not a current user? Sign up!